Synthesis and immunogenicity of PG-tb1 monovalent glycoconjugate

Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis

“…Similarly, ssDNA aptamers were developed to suppress the immunomodulatory properties of LAM leading to control of bacterial replication in animal models [73,74]. Other Mtb cell surface components, such as phenolic glycolipids, have also been targeted with conjugate vaccines [75]. However, in none of these studies was evidence of a direct contribution of vaccine-induced Abs provided.…”

Synthesis and immunogenicity of theMycobacterium tuberculosisarabinomannan–CRM197 conjugate

“…M.p. (20). Residue 19 (21 mg, 0.006 mmol) was dissolved in anhydrous THF (10 mL) and the solution was added dropwise to a dark blue solution of sodium in liquid ammonia at −78°C.…”

“…[15][16][17][18][19] To develop an effective subunit type of TB vaccine and reduce the immunosuppressive effect of the whole LAM molecule, the lipid of LAM was removed resulting in T-helper independent antigens, which can often be circumvented by covalently linking to T-helper cell containing carrier proteins. [20][21][22][23] Overall, high titers of antibody against LAM are often observed in active MTB. [24][25][26] The detailed structural features of LAM were demonstrated in the 1990s.…”

Developments in the Synthesis of Mycobacterial Phenolic Glycolipids

“…To explore the use of M. tuberculosis PGLs in diagnostics, vaccine purposes and enable interaction studies at the molecular level, various syntheses of the MTb PGLs and pHBADs have been developed as well. [25,31,56,73,[77][78][79] The structures of the Mtb PGL glycoforms are depicted in Figure 3. The general structure consists of two α (1!3) linked rhamnoses which are α (1!3) linked to an L-fucose residue on the non-reducing end.…”